<p>仅仅因为一家公司没有盈利，并不意味着其股票会下跌。事实上，<strong>Immuneering</strong>（NASDAQ:IMRX）股票在过去一年上涨了 248%，为股东带来了丰厚的收益。但尽管历史赞美那些罕见的成功案例，失败的案例往往被遗忘；谁还记得 Pets.com？</p>
<p>因此，尽管股价高涨，我们认为值得问问 <strong>Immuneering</strong> 的现金消耗是否过于风险。在本文中，我们将现金消耗定义为其年度（负）自由现金流，即公司每年用于资助其增长的资金。第一步是将其现金消耗与现金储备进行比较，以给出其 “现金跑道”。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——仍然有机会提前入场。</p>
<h2><strong>Immuneering</strong> 的现金跑道有多长？</h2>
<p>现金跑道被定义为公司在保持当前现金消耗率的情况下，耗尽资金所需的时间。到 2025 年 9 月，<strong>Immuneering</strong> 拥有 2.28 亿美元的现金，并且没有债务。在过去一年中，其现金消耗为 5000 万美元。因此，从 2025 年 9 月起，它有 4.5 年的现金跑道。毫无疑问，这是一条令人安心的长跑道。如下图所示，您可以看到其现金持有量随时间的变化。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/308350677-debt-equity-history-analysis-1-dark-2/1763813804570?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/308350677-debt-equity-history-analysis-1-dark-2/1763813804570"/></p>
<p>NasdaqGM:IMRX2025 年 11 月 22 日的债务与股本历史</p>
<p>查看我们对 <strong>Immuneering</strong> 的最新分析</p>
<h2><strong>Immuneering</strong> 的现金消耗随时间变化如何？</h2>
<p><strong>Immuneering</strong> 在过去一年没有记录任何收入，这表明它是一家仍在发展业务的早期阶段公司。因此，虽然我们无法通过销售来理解增长，但我们可以通过观察现金消耗的变化来了解支出随时间的趋势。现金消耗下降了 4.7%，这似乎表明管理层认为公司在以适当的速度推进其商业计划方面支出足够。然而，关键因素显然是公司未来是否会增长。因此，您可能想看看公司在未来几年预计会增长多少。</p>
<h2><strong>Immuneering</strong> 能否轻松筹集更多现金？</h2>
<p>尽管 <strong>Immuneering</strong> 的现金消耗显著减少，但仍值得考虑它能多容易地筹集更多现金，即使只是为了加速增长。公司可以通过债务或股权筹集资金。通常，一家公司会出售新股以筹集现金并推动增长。我们可以将公司的现金消耗与其市值进行比较，以了解公司需要发行多少新股来资助一年的运营。</p>
<p>由于其市值为 4.51 亿美元，<strong>Immuneering</strong> 的 5000 万美元现金消耗约占其市场价值的 11%。因此，我们认为该公司可以相对轻松地筹集更多现金以支持增长，尽管这会导致一定的稀释。</p>
<h2><strong>Immuneering</strong> 的现金消耗情况有多风险？</h2>
<p>如您所见，我们对 <strong>Immuneering</strong> 的现金消耗并不太担心。特别是，我们认为其现金跑道突显出公司对支出的掌控良好。其弱点在于现金消耗的减少，但即便如此也并不算太糟糕！综合考虑本文中的所有指标，我们对其现金消耗率并不担心；公司似乎很好地掌握了中期的支出需求。深入分析后，我们发现 <strong>Immuneering</strong> 有 4 个警示信号需要您注意，其中 2 个令人有些担忧。</p>
<p>当然，<strong>您可能会通过寻找其他地方找到一个绝佳的投资机会。</strong> 因此，请查看这份 <strong>免费</strong> 的公司内部持股显著的名单，以及这份根据分析师预测的成长股名单。</p>

IMRX

<p>Immuneering（纳斯达克代码：IMRX）在过去一年中股价上涨了 248%。尽管没有收入，该公司截至 2025 年 9 月拥有 228 百万美元的现金和无债务，现金流可支持 4.5 年。其现金消耗减少了 4.7%，表明支出得到控制。以 4.51 亿美元的市值来看，筹集额外资金似乎是可行的。总体而言，Immuneering 的现金消耗情况看起来可控，但仍需考虑一些警示信号</p>

<p>Just because a business does not make any money, does not mean that the stock will go down. Indeed, <strong>Immuneering</strong> (NASDAQ:IMRX) stock is up 248% in the last year, providing strong gains for shareholders. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?</p>
<div class="lb-trans"><p>仅仅因为一家公司没有盈利，并不意味着其股票会下跌。事实上，<strong>Immuneering</strong>（NASDAQ:IMRX）股票在过去一年上涨了 248%，为股东带来了丰厚的收益。但尽管历史赞美那些罕见的成功案例，失败的案例往往被遗忘；谁还记得 Pets.com？</p>
</div><p>So notwithstanding the buoyant share price, we think it's well worth asking whether Immuneering's cash burn is too risky. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.</p>
<div class="lb-trans"><p>因此，尽管股价高涨，我们认为值得问问 <strong>Immuneering</strong> 的现金消耗是否过于风险。在本文中，我们将现金消耗定义为其年度（负）自由现金流，即公司每年用于资助其增长的资金。第一步是将其现金消耗与现金储备进行比较，以给出其 “现金跑道”。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——仍然有机会提前入场。</p>
</div><h2>How Long Is Immuneering's Cash Runway?</h2>
<div class="lb-trans"><h2><strong>Immuneering</strong> 的现金跑道有多长？</h2>
</div><p>A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. In September 2025, Immuneering had US$228m in cash, and was debt-free. In the last year, its cash burn was US$50m. Therefore, from September 2025 it had 4.5 years of cash runway. There's no doubt that this is a reassuringly long runway. Depicted below, you can see how its cash holdings have changed over time.</p>
<div class="lb-trans"><p>现金跑道被定义为公司在保持当前现金消耗率的情况下，耗尽资金所需的时间。到 2025 年 9 月，<strong>Immuneering</strong> 拥有 2.28 亿美元的现金，并且没有债务。在过去一年中，其现金消耗为 5000 万美元。因此，从 2025 年 9 月起，它有 4.5 年的现金跑道。毫无疑问，这是一条令人安心的长跑道。如下图所示，您可以看到其现金持有量随时间的变化。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/308350677-debt-equity-history-analysis-1-dark-2/1763813804570" alt="" original-src="https://images.simplywall.st/asset/chart/308350677-debt-equity-history-analysis-1-dark-2/1763813804570"/></p>
<p>NasdaqGM:IMRX Debt to Equity History November 22nd 2025</p>
<div class="lb-trans"><p>NasdaqGM:IMRX2025 年 11 月 22 日的债务与股本历史</p>
</div><p>See our latest analysis for Immuneering</p>
<div class="lb-trans"><p>查看我们对 <strong>Immuneering</strong> 的最新分析</p>
</div><h2>How Is Immuneering's Cash Burn Changing Over Time?</h2>
<div class="lb-trans"><h2><strong>Immuneering</strong> 的现金消耗随时间变化如何？</h2>
</div><p>Immuneering didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. With cash burn dropping by 4.7% it seems management feel the company is spending enough to advance its business plans at an appropriate pace. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years.</p>
<div class="lb-trans"><p><strong>Immuneering</strong> 在过去一年没有记录任何收入，这表明它是一家仍在发展业务的早期阶段公司。因此，虽然我们无法通过销售来理解增长，但我们可以通过观察现金消耗的变化来了解支出随时间的趋势。现金消耗下降了 4.7%，这似乎表明管理层认为公司在以适当的速度推进其商业计划方面支出足够。然而，关键因素显然是公司未来是否会增长。因此，您可能想看看公司在未来几年预计会增长多少。</p>
</div><h2>Can Immuneering Raise More Cash Easily?</h2>
<div class="lb-trans"><h2><strong>Immuneering</strong> 能否轻松筹集更多现金？</h2>
</div><p>While Immuneering is showing a solid reduction in its cash burn, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Companies can raise capital through either debt or equity. Commonly, a business will sell new shares in itself to raise cash and drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.</p>
<div class="lb-trans"><p>尽管 <strong>Immuneering</strong> 的现金消耗显著减少，但仍值得考虑它能多容易地筹集更多现金，即使只是为了加速增长。公司可以通过债务或股权筹集资金。通常，一家公司会出售新股以筹集现金并推动增长。我们可以将公司的现金消耗与其市值进行比较，以了解公司需要发行多少新股来资助一年的运营。</p>
</div><p>Since it has a market capitalisation of US$451m, Immuneering's US$50m in cash burn equates to about 11% of its market value. As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution.</p>
<div class="lb-trans"><p>由于其市值为 4.51 亿美元，<strong>Immuneering</strong> 的 5000 万美元现金消耗约占其市场价值的 11%。因此，我们认为该公司可以相对轻松地筹集更多现金以支持增长，尽管这会导致一定的稀释。</p>
</div><h2>How Risky Is Immuneering's Cash Burn Situation?</h2>
<div class="lb-trans"><h2><strong>Immuneering</strong> 的现金消耗情况有多风险？</h2>
</div><p>As you can probably tell by now, we're not too worried about Immuneering's cash burn. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. Its weak point is its cash burn reduction, but even that wasn't too bad! Looking at all the measures in this article, together, we're not worried about its rate of cash burn; the company seems well on top of its medium-term spending needs. Taking a deeper dive, we've spotted <strong>4 warning signs for Immuneering</strong> you should be aware of, and 2 of them are a bit concerning.</p>
<div class="lb-trans"><p>如您所见，我们对 <strong>Immuneering</strong> 的现金消耗并不太担心。特别是，我们认为其现金跑道突显出公司对支出的掌控良好。其弱点在于现金消耗的减少，但即便如此也并不算太糟糕！综合考虑本文中的所有指标，我们对其现金消耗率并不担心；公司似乎很好地掌握了中期的支出需求。深入分析后，我们发现 <strong>Immuneering</strong> 有 4 个警示信号需要您注意，其中 2 个令人有些担忧。</p>
</div><p>Of course, <strong>you might find a fantastic investment by looking elsewhere.</strong> So take a peek at this <strong>free</strong> list of companies with significant insider holdings, and this list of stocks growth stocks (according to analyst forecasts)</p>
<div class="lb-trans"><p>当然，<strong>您可能会通过寻找其他地方找到一个绝佳的投资机会。</strong> 因此，请查看这份 <strong>免费</strong> 的公司内部持股显著的名单，以及这份根据分析师预测的成长股名单。</p>
</div>

像 Immuneering（NASDAQ:IMRX）这样的公司有能力进行增长投资